Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin

T. Milota, M. Bloomfield, P. Kralickova, D. Jilek, V. Novak, J. Litzman, H. Posova, L. Mrazova, J. Poloniova, M. Prucha, P. Rozsival, V. Rauschova, G. Philipp, A. Sediva,

. 2019 ; 41 (11) : 2231-2238. [pub] 20190926

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze IV, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025526
E-zdroje Online Plný text

NLK ProQuest Central od 2002-01-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2002-01-01 do Před 2 měsíci
Health Management Database (ProQuest) od 2002-01-01 do Před 2 měsíci

Odkazy

PubMed 31564514
DOI 10.1016/j.clinthera.2019.08.013
Knihovny.cz E-zdroje

PURPOSE: Immunoglobulin substitution therapy is an essential therapeutic approach for patients with primary antibody deficiencies. Different methods of administration, including intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) preparations, provide effective and tolerable treatment and enable the adjustment of therapy to patients' needs. A new 20% SCIG represents a new therapeutic option and a new route of administration using rapid-push application. The aim of the Czech Hizentra Noninterventional Study With Rapid Push (CHHINSTRAP) is to evaluate patient satisfaction with as well as the tolerability and efficacy of nonmedical switch to 20% SCIG from previous treatment with IVIG or SCIG and rapid push as a new way to administer SCIG. CHHINSTRAP is the first Phase IV, noninterventional, open-label, prospective, multicentric study of this type conducted in Central and Eastern Europe. METHODS: Primary end points, including efficacy, adverse effects, convenience of use, and overall satisfaction, were evaluated by Treatment Satisfaction Questionnaire for Medication version II. Secondary end points, such as serum IgG trough levels, infusion duration, number of application sites, frequency of infections, related hospital admissions, and antibiotic consumption, were obtained from patients at each follow-up visit. FINDINGS: Together, 50 eligible patients with primary antibody deficiency were switched from SCIG or IVIG to an equivalent dose of 20% SCIG and were followed up for 12 months during 5 consecutive visits. The results indicate that patients switched from previous IVIG or SCIG preparations had significantly higher serum trough IgG levels and a lower incidence of infections and related events, such as hospital admissions or consumption of antibiotics. These findings were also reflected in gradually increasing convenience of use and overall satisfaction reported by patients. Apart from duration of application, no differences were found between patients previously receiving SCIG or IVIG. Moreover, our study found a high level of safety of 20% SCIG rapid push, which was comparable to other preparations and application methods. IMPLICATIONS: On the basis of the results of CHHINSTRAP study, we conclude that 20% SCIG is a tolerable and effective immunoglobulin preparation, representing a new therapeutic approach in patients with primary antibody deficiencies. Its efficacy and tolerability have been found in patients on nonmedical switch from previous treatment with IVIG or SCIG.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025526
003      
CZ-PrNML
005      
20240313092501.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clinthera.2019.08.013 $2 doi
035    __
$a (PubMed)31564514
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Milota, Tomas $u Department of Immunology, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: tomas.milota@fnmotol.cz.
245    10
$a Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin / $c T. Milota, M. Bloomfield, P. Kralickova, D. Jilek, V. Novak, J. Litzman, H. Posova, L. Mrazova, J. Poloniova, M. Prucha, P. Rozsival, V. Rauschova, G. Philipp, A. Sediva,
520    9_
$a PURPOSE: Immunoglobulin substitution therapy is an essential therapeutic approach for patients with primary antibody deficiencies. Different methods of administration, including intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) preparations, provide effective and tolerable treatment and enable the adjustment of therapy to patients' needs. A new 20% SCIG represents a new therapeutic option and a new route of administration using rapid-push application. The aim of the Czech Hizentra Noninterventional Study With Rapid Push (CHHINSTRAP) is to evaluate patient satisfaction with as well as the tolerability and efficacy of nonmedical switch to 20% SCIG from previous treatment with IVIG or SCIG and rapid push as a new way to administer SCIG. CHHINSTRAP is the first Phase IV, noninterventional, open-label, prospective, multicentric study of this type conducted in Central and Eastern Europe. METHODS: Primary end points, including efficacy, adverse effects, convenience of use, and overall satisfaction, were evaluated by Treatment Satisfaction Questionnaire for Medication version II. Secondary end points, such as serum IgG trough levels, infusion duration, number of application sites, frequency of infections, related hospital admissions, and antibiotic consumption, were obtained from patients at each follow-up visit. FINDINGS: Together, 50 eligible patients with primary antibody deficiency were switched from SCIG or IVIG to an equivalent dose of 20% SCIG and were followed up for 12 months during 5 consecutive visits. The results indicate that patients switched from previous IVIG or SCIG preparations had significantly higher serum trough IgG levels and a lower incidence of infections and related events, such as hospital admissions or consumption of antibiotics. These findings were also reflected in gradually increasing convenience of use and overall satisfaction reported by patients. Apart from duration of application, no differences were found between patients previously receiving SCIG or IVIG. Moreover, our study found a high level of safety of 20% SCIG rapid push, which was comparable to other preparations and application methods. IMPLICATIONS: On the basis of the results of CHHINSTRAP study, we conclude that 20% SCIG is a tolerable and effective immunoglobulin preparation, representing a new therapeutic approach in patients with primary antibody deficiencies. Its efficacy and tolerability have been found in patients on nonmedical switch from previous treatment with IVIG or SCIG.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a dítě $7 D002648
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunoglobulin G $x aplikace a dávkování $x škodlivé účinky $7 D007074
650    _2
$a syndromy imunologické nedostatečnosti $x farmakoterapie $7 D007153
650    _2
$a subkutánní infuze $7 D055104
650    _2
$a injekce subkutánní $7 D007279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a spokojenost pacientů $7 D017060
650    _2
$a průzkumy a dotazníky $7 D011795
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Česká republika $7 D018153
655    _2
$a klinické zkoušky, fáze IV $7 D017429
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bloomfield, Marketa $u Department of Immunology, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Pediatrics, Thomayer's Hospital, Prague, Czech Republic and 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Kralickova, Pavlina $u Institute of Clinical Immunology and Allergy, University Hospital Hradec Kralove, Faculty of Medicine, Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Jilek, Dalibor $u Centre of Immunology and Microbiology, Regional Institute of Public Health, Usti nad Labem, Czech Republic.
700    1_
$a Novak, Vitezslav $u Department of Immunology and Allergy, Public Health Institute Ostrava, Ostrava, Czech Republic.
700    1_
$a Litzman, Jiri $u Department of Clinical Immunology Allergy, St Annés University Hospital, Brno, Czech Republic; Faculty of Medicicne, Masaryk University, Brno, Czech Republic.
700    1_
$a Posova, Helena $u Institute of Immunology 1st Medical Faculty, Charles University, Prague, Czech Republic.
700    1_
$a Mrazova, Lucie $u Allergy and Clinical Immunology, Regional Hospital in Ceske Budejovice, Czech Republic.
700    1_
$a Poloniová, Jana $u Allergy and Clinical Immunology, Regional Hospital in Ceske Budejovice, Czech Republic. $7 xx0314787
700    1_
$a Prucha, Miroslav $u Department of Clinical Biochemistry, Haematology and Immunology, Na Homolce Hospital, Prague, Czech Republic.
700    1_
$a Rozsival, Pavel $u Department of Pediatrics, University Hospital Hradec Kralove, Faculty of Medicine, Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Rauschova, Vlasta $u CSL Behring s.r.o, Prague, Czech Republic.
700    1_
$a Philipp, Gunnar $u CSL Behring AG, Bern, Switzerland.
700    1_
$a Sediva, Anna $u Department of Immunology, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
773    0_
$w MED00001165 $t Clinical therapeutics $x 1879-114X $g Roč. 41, č. 11 (2019), s. 2231-2238
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31564514 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20240313092456 $b ABA008
999    __
$a ok $b bmc $g 1599671 $s 1116212
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 41 $c 11 $d 2231-2238 $e 20190926 $i 1879-114X $m Clinical therapeutics $n Clin Ther $x MED00001165
LZP    __
$a Pubmed-20201125
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace